Article

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

Division of Infectious Disease, Department of Internal Medicine, University of California at Davis, Sacramento, CA 95618, USA.
The Journal of Infectious Diseases (Impact Factor: 5.78). 11/2009; 201(1):132-41. DOI: 10.1086/648591
Source: PubMed

ABSTRACT We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines.
Healthy HIV-uninfected adults were enrolled in 6 blinded placebo-controlled studies evaluating the immunogenicity of (1) a 4-dose regimen of a DNA vaccine, (2) a 3-dose priming regimen of the DNA vaccine with a booster dose of an adenovirus type 5 (Ad5)-vectored vaccine, or (3) a 3-dose regimen of the Ad5 vaccine. The DNA plasmid was provided with or without an aluminum phosphate or CRL1005 adjuvant. The primary end point was the unfractionated HIV-1 gag-specific interferon gamma enzyme-linked immunospot (ELISpot) response 4 weeks after the final dose.
Overall, 254 (83%) of 307 subjects randomized to the vaccine groups were evaluable. Adjuvants did not enhance immunogenicity of the DNA vaccine. Postboost ELISpot responder frequencies were higher for Ad5-containing regimens than for the DNA/DNA regimen (33%) but were similar for DNA/Ad5 (55%) and Ad5/Ad5 (50%). DNA/DNA elicited mainly a CD4 response, whereas Ad5/Ad5 elicited mainly a CD8 response; DNA/Ad5 generated CD4 and CD8 responses comparable to those of DNA/DNA and Ad5/Ad5, respectively.
The DNA vaccine alone or as a priming regimen for the Ad5 vaccine did not increase unfractionated ELISpot responses compared with the Ad5 vaccine alone. Qualitative T cell responses to different vaccine regimens deserve further study.

0 Followers
 · 
120 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Adenoviruses (Ads) have attracted researchers from across the disciplines for several reasons. Their ability to recombine with and express the heterologous genes encouraged their development as gene/vaccine delivery vectors. Preclinical and clinical trials using these vectors have shown significant promise for their future development while highlighting certain limitations. Areas covered: Ad vector development, clinical application of these vectors in gene therapy and vaccine development, and promises that these vectors offered for future development are discussed. Also, various factors affecting their in vivo efficacy as well as the strategies being pursued to overcome these obstacles are described. Expert opinion: Decades of efforts have resulted in understanding various aspects of human Ad 5 biology as well as the in vivo behavior of vectors derived from this serotype. While this vector has shown great potential, some of the limitations highlighted in recent studies have reinforced the quest for an ideal vector derived from novel Ads. Combinatorial approaches to address the various limitations of the existing vectors must be pursued to develop novel vectors with enhanced clinical potential.
    Expert Opinion on Biological Therapy 12/2014; 15(3):1-15. DOI:10.1517/14712598.2015.993374 · 3.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The immunogenicity results from 3 phase I trials of the Merck DNA human immunodeficiency virus (HIV) vaccine have previously been reported. Because preventive DNA vaccine strategies continue to be leveraged for diverse infections, the safety and tolerability results from these studies can inform the field moving forward, particularly regarding adverse reactions and adjuvants. No serious vaccine-related adverse events were reported during the 3-dose priming phase. Pain at the injection site was more common with adjuvanted formulations than with the phosphate-buffered saline diluent alone. Febrile reactions were usually low grade. Although the AlPO4 or CRL1005 adjuvants used in these studies did not significantly enhance the immunogenicity of the DNA vaccine, adverse events were numerically more common with adjuvanted formulations than without adjuvants.
    03/2014; 1(1):ofu016. DOI:10.1093/ofid/ofu016
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency viruses 1 and 2 (HIV-1, 2) present a public health problem for which there is neither an effective antiviral therapy nor a preventive vaccine. In this study, the immune responses of mice to prime-boost vaccination with the recombinant DNA (rDNA) and recombinant Fowlpox virus (rFPV) both expressing HIV-2 Gag-gp105 chimeric protein, were compared to those elicited by each vector alone. Mice primed with the rDNA and boosted with the rFPV showed HIV-2-specific antibody levels, splenic CD4+ and CD8+ T-lymphocyte numbers, and Gag-gp105-specific cytotoxic T-lymphocytes (CTL) activity increased by 20-30% as compared with those elicited by these vaccines alone. These findings suggested that the prime-boost strategy combining rDNA and rFPV elicited significant Gag-gp105 - specific cellular and humoral immune responses, thus supporting this novel approach to the immunization against HIV infections.
    Acta virologica 12/2010; 54(4):293-6. DOI:10.4149/av_2010_04_293 · 1.04 Impact Factor